194 related articles for article (PubMed ID: 35805938)
21. Glucocerebrosidase enzyme activity in GBA mutation Parkinson's disease.
Ortega RA; Torres PA; Swan M; Nichols W; Boschung S; Raymond D; Barrett MJ; Johannes BA; Severt L; Shanker V; Hunt AL; Bressman S; Pastores GM; Saunders-Pullman R
J Clin Neurosci; 2016 Jun; 28():185-6. PubMed ID: 26857292
[TBL] [Abstract][Full Text] [Related]
22. Alpha-synuclein interacts with Glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases.
Yap TL; Gruschus JM; Velayati A; Westbroek W; Goldin E; Moaven N; Sidransky E; Lee JC
J Biol Chem; 2011 Aug; 286(32):28080-8. PubMed ID: 21653695
[TBL] [Abstract][Full Text] [Related]
23. Metabolic syndrome does not influence the phenotype of LRRK2 and GBA related Parkinson's disease.
Thaler A; Shenhar-Tsarfaty S; Shaked Y; Gurevich T; Omer N; Bar-Shira A; Gana-Weisz M; Goldstein O; Kestenbaum M; Cedarbaum JM; Orr-Urtreger A; Giladi N; Mirelman A
Sci Rep; 2020 Jun; 10(1):9329. PubMed ID: 32518334
[TBL] [Abstract][Full Text] [Related]
24. Direct targeting of wild-type glucocerebrosidase by antipsychotic quetiapine improves pathogenic phenotypes in Parkinson's disease models.
Burbulla LF; Zheng J; Song P; Jiang W; Johnson ME; Brundin P; Krainc D
JCI Insight; 2021 Oct; 6(19):. PubMed ID: 34622801
[TBL] [Abstract][Full Text] [Related]
25. Lysosomal impairment in Parkinson's disease.
Dehay B; Martinez-Vicente M; Caldwell GA; Caldwell KA; Yue Z; Cookson MR; Klein C; Vila M; Bezard E
Mov Disord; 2013 Jun; 28(6):725-32. PubMed ID: 23580333
[TBL] [Abstract][Full Text] [Related]
26. Precision medicine in Parkinson's disease patients with LRRK2 and GBA risk variants - Let's get even more personal.
von Linstow CU; Gan-Or Z; Brundin P
Transl Neurodegener; 2020 Oct; 9(1):39. PubMed ID: 33066808
[TBL] [Abstract][Full Text] [Related]
27. Fibroblasts from idiopathic Parkinson's disease exhibit deficiency of lysosomal glucocerebrosidase activity associated with reduced levels of the trafficking receptor LIMP2.
Thomas R; Moloney EB; Macbain ZK; Hallett PJ; Isacson O
Mol Brain; 2021 Jan; 14(1):16. PubMed ID: 33468204
[TBL] [Abstract][Full Text] [Related]
28. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.
Simuni T; Uribe L; Cho HR; Caspell-Garcia C; Coffey CS; Siderowf A; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Tosun D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten SJ; Bressman S; Marek K;
Lancet Neurol; 2020 Jan; 19(1):71-80. PubMed ID: 31678032
[TBL] [Abstract][Full Text] [Related]
29. A Possible Modifying Effect of the G2019S Mutation in the LRRK2 Gene on GBA Parkinson's Disease.
Omer N; Giladi N; Gurevich T; Bar-Shira A; Gana-Weisz M; Goldstein O; Kestenbaum M; Cedarbaum JM; Orr-Urtreger A; Mirelman A; Thaler A
Mov Disord; 2020 Jul; 35(7):1249-1253. PubMed ID: 32353202
[TBL] [Abstract][Full Text] [Related]
30. Carriers of both GBA and LRRK2 mutations, compared to carriers of either, in Parkinson's disease: Risk estimates and genotype-phenotype correlations.
Yahalom G; Greenbaum L; Israeli-Korn S; Fay-Karmon T; Livneh V; Ruskey JA; Roncière L; Alam A; Gan-Or Z; Hassin-Baer S
Parkinsonism Relat Disord; 2019 May; 62():179-184. PubMed ID: 30573413
[TBL] [Abstract][Full Text] [Related]
31. Prevalence of pre-diagnostic symptoms did not differ between LRRK2-related, GBA-related and idiopathic patients with Parkinson's disease.
Liu SY; Zheng Z; Gu ZQ; Wang CD; Tang BS; Xu YM; Ma JH; Zhou YT; Feng T; Chen SD; Chan P;
Parkinsonism Relat Disord; 2018 Dec; 57():72-76. PubMed ID: 30119933
[TBL] [Abstract][Full Text] [Related]
32. GBA1-and LRRK2-directed Treatments: The Way Forward.
Maayan Eshed G; Alcalay RN
Parkinsonism Relat Disord; 2024 May; 122():106039. PubMed ID: 38438297
[TBL] [Abstract][Full Text] [Related]
33. Glucocerebrosidase and Parkinson disease: Recent advances.
Schapira AH
Mol Cell Neurosci; 2015 May; 66(Pt A):37-42. PubMed ID: 25802027
[TBL] [Abstract][Full Text] [Related]
34. LRRK2 interacts with the vacuolar-type H+-ATPase pump a1 subunit to regulate lysosomal function.
Wallings R; Connor-Robson N; Wade-Martins R
Hum Mol Genet; 2019 Aug; 28(16):2696-2710. PubMed ID: 31039583
[TBL] [Abstract][Full Text] [Related]
35. Clinical profiles associated with LRRK2 and GBA mutations in Brazilians with Parkinson's disease.
da Silva CP; de M Abreu G; Cabello Acero PH; Campos M; Pereira JS; de A Ramos SR; Nascimento CM; Voigt DD; Rosso AL; Araujo Leite MA; Vasconcellos LFR; Nicaretta DH; Della Coletta MV; da Silva DJ; Gonçalves AP; Dos Santos JM; Calassara V; Valença DCT; de M Martins CJ; Santos-Rebouças CB; Pimentel MMG
J Neurol Sci; 2017 Oct; 381():160-164. PubMed ID: 28991672
[TBL] [Abstract][Full Text] [Related]
36. Mutations in GBA and LRRK2 Are Not Associated with Increased Inflammatory Markers.
Thaler A; Omer N; Giladi N; Gurevich T; Bar-Shira A; Gana-Weisz M; Goldstein O; Kestenbaum M; Shirvan JC; Cedarbaum JM; Orr-Urtreger A; Regev K; Shenhar-Tsarfaty S; Mirelman A
J Parkinsons Dis; 2021; 11(3):1285-1296. PubMed ID: 33998549
[TBL] [Abstract][Full Text] [Related]
37. Pathogenic LRRK2 mutations, through increased kinase activity, produce enlarged lysosomes with reduced degradative capacity and increase ATP13A2 expression.
Henry AG; Aghamohammadzadeh S; Samaroo H; Chen Y; Mou K; Needle E; Hirst WD
Hum Mol Genet; 2015 Nov; 24(21):6013-28. PubMed ID: 26251043
[TBL] [Abstract][Full Text] [Related]
38. Survival rates among Parkinson's disease patients who carry mutations in the LRRK2 and GBA genes.
Thaler A; Kozlovski T; Gurevich T; Bar-Shira A; Gana-Weisz M; Orr-Urtreger A; Giladi N; Mirelman A
Mov Disord; 2018 Oct; 33(10):1656-1660. PubMed ID: 30288804
[TBL] [Abstract][Full Text] [Related]
39. Preclinical modeling of chronic inhibition of the Parkinson's disease associated kinase LRRK2 reveals altered function of the endolysosomal system in vivo.
Kluss JH; Mazza MC; Li Y; Manzoni C; Lewis PA; Cookson MR; Mamais A
Mol Neurodegener; 2021 Mar; 16(1):17. PubMed ID: 33741046
[TBL] [Abstract][Full Text] [Related]
40. Age at Onset of Parkinson's Disease Among Ashkenazi Jewish Patients: Contribution of Environmental Factors, LRRK2 p.G2019S and GBA p.N370S Mutations.
Yahalom G; Rigbi A; Israeli-Korn S; Krohn L; Rudakou U; Ruskey JA; Benshimol L; Tsafnat T; Gan-Or Z; Hassin-Baer S; Greenbaum L
J Parkinsons Dis; 2020; 10(3):1123-1132. PubMed ID: 32310186
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
